WO2006087476A3 - Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique - Google Patents

Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique Download PDF

Info

Publication number
WO2006087476A3
WO2006087476A3 PCT/FR2006/000356 FR2006000356W WO2006087476A3 WO 2006087476 A3 WO2006087476 A3 WO 2006087476A3 FR 2006000356 W FR2006000356 W FR 2006000356W WO 2006087476 A3 WO2006087476 A3 WO 2006087476A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
therapeutics
application
preparation
same
Prior art date
Application number
PCT/FR2006/000356
Other languages
English (en)
Other versions
WO2006087476A2 (fr
Inventor
Francis Barth
Christian Congy
Laurent Hortala
Murielle Rinaldi-Carmona
Original Assignee
Sanofi Aventis
Francis Barth
Christian Congy
Laurent Hortala
Murielle Rinaldi-Carmona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis, Francis Barth, Christian Congy, Laurent Hortala, Murielle Rinaldi-Carmona filed Critical Sanofi Aventis
Priority to BRPI0608866-0A priority Critical patent/BRPI0608866A2/pt
Priority to AU2006215521A priority patent/AU2006215521A1/en
Priority to EP06709331A priority patent/EP1853557A2/fr
Priority to JP2007555665A priority patent/JP2008530187A/ja
Priority to CA002597033A priority patent/CA2597033A1/fr
Publication of WO2006087476A2 publication Critical patent/WO2006087476A2/fr
Priority to US11/832,851 priority patent/US7524971B2/en
Priority to IL185034A priority patent/IL185034A0/en
Publication of WO2006087476A3 publication Critical patent/WO2006087476A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)

Abstract

La présente invention a pour objet des composés répondant à la formule (I) dans laquelle : - X représente un groupe : formule (II) ; - R1 et R6 représentent un atome d'hydrogène ou un groupe alkyle ; - R2 représente un radical choisi parmi : un (C1-C12)alkyle ; un radical carbocyclique non aromatique en (C3-C12) ; un (C3-C7)cycloalkylméthyle ; un phényle, un benzyle, un benzhydryle, un benzhydrylméthyle, un phénéthyle ; un benzodioxolyle, un dihydrobenzofuranyle, un dihydrobenzodioxinyle ; un méthyle substitué par un benzodioxolyle, un dihydrobenzofuranyle, un dihydrobenzodioxinyle ; un 1, 2, 3, 4-tétrahydronaphtalènyle non substitué ou ; un radical hétérocyclique, un indolyle, un benzothiazolyle non substitué ou substitué ; les dits radicaux étant non substitués ou substitués ; - R3 représente un (C1 -C5)alkyle ou un (C3-C7) cycloalkyle ;- R4 et R5 représentent un phényle non substitué ou substitué ; Procédé de préparation et application en thérapeutique.
PCT/FR2006/000356 2005-02-17 2006-02-16 Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique WO2006087476A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BRPI0608866-0A BRPI0608866A2 (pt) 2005-02-17 2006-02-16 derivados de 1,5-diarilpirrol, o respectivo preparo, medicamento, composição farmacêutica e uso
AU2006215521A AU2006215521A1 (en) 2005-02-17 2006-02-16 1,5-diarylpyrrole derivatives, preparation method thereof and application of same in therapeutics
EP06709331A EP1853557A2 (fr) 2005-02-17 2006-02-16 Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
JP2007555665A JP2008530187A (ja) 2005-02-17 2006-02-16 １，５−ジアリールピロール誘導体、この調製方法および治療剤におけるこの適用
CA002597033A CA2597033A1 (fr) 2005-02-17 2006-02-16 Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
US11/832,851 US7524971B2 (en) 2005-02-17 2007-08-02 1,5-diarylpyrrole derivatives, preparation method thereof and application of same in therapeutics
IL185034A IL185034A0 (en) 2005-02-17 2007-08-02 1,5-diarylpyrrole derivatives, preparation method thereof and application of same in therapeutics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501660 2005-02-17
FR0501660A FR2882054B1 (fr) 2005-02-17 2005-02-17 Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/832,851 Continuation US7524971B2 (en) 2005-02-17 2007-08-02 1,5-diarylpyrrole derivatives, preparation method thereof and application of same in therapeutics

Publications (2)

Publication Number Publication Date
WO2006087476A2 WO2006087476A2 (fr) 2006-08-24
WO2006087476A3 true WO2006087476A3 (fr) 2007-08-09

Family

ID=34954653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/000356 WO2006087476A2 (fr) 2005-02-17 2006-02-16 Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique

Country Status (18)

Country Link
US (1) US7524971B2 (fr)
EP (1) EP1853557A2 (fr)
JP (1) JP2008530187A (fr)
KR (1) KR20070103454A (fr)
CN (1) CN101119967A (fr)
AR (1) AR052673A1 (fr)
AU (1) AU2006215521A1 (fr)
BR (1) BRPI0608866A2 (fr)
CA (1) CA2597033A1 (fr)
DO (1) DOP2006000043A (fr)
FR (1) FR2882054B1 (fr)
IL (1) IL185034A0 (fr)
PA (1) PA8663601A1 (fr)
RU (1) RU2007134383A (fr)
SV (1) SV2007002420A (fr)
TW (1) TW200714585A (fr)
UY (1) UY29373A1 (fr)
WO (1) WO2006087476A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2874012B1 (fr) * 2004-08-09 2008-08-22 Sanofi Synthelabo Derives de pyrrole, leur preparation et leur utlisation en therapeutique
FR2894579B1 (fr) * 2005-12-12 2008-01-18 Sanofi Aventis Sa Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
WO2008017381A1 (fr) 2006-08-08 2008-02-14 Sanofi-Aventis Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituée, son procédé de fabrication, médicament contenant ce composé et son utilisation
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
FR2930939B1 (fr) * 2008-05-09 2010-07-30 Sanofi Aventis Derives de pyrrole, leur preparation et leur application en therapeutique
EP2310372B1 (fr) 2008-07-09 2012-05-23 Sanofi Composés hétérocycliques, leur procédé de préparation, médicaments les contenant et leur utilisation
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
EP2470552B1 (fr) 2009-08-26 2013-11-13 Sanofi Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, produits pharmaceutiques comprenant ces composés et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
GB201103419D0 (fr) 2011-02-28 2011-04-13 Univ Aberdeen
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2921147C (fr) 2012-08-20 2018-01-23 Thomas M. Espinosa Supports d'ancre et ensembles d'ancrage pour des ponts metalliques
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
US20180022698A1 (en) 2014-10-16 2018-01-25 The Board Of Trustees Of The Leland Stanford Junior University Novel methods, compounds, and compositions for anesthesia
CN104478781A (zh) * 2015-01-13 2015-04-01 佛山市赛维斯医药科技有限公司 二烯金刚烷类化合物、其制备方法和用途
CN104447484B (zh) * 2015-01-13 2016-06-08 佛山市赛维斯医药科技有限公司 含烷氧苯基和二烯金刚烷结构的化合物、其制备方法和用途
CN104478782B (zh) * 2015-01-13 2016-03-16 佛山市赛维斯医药科技有限公司 一类含烷氧苯基和二烯氟代金刚烷结构的化合物和用途
CN104496879A (zh) * 2015-01-13 2015-04-08 佛山市赛维斯医药科技有限公司 一种含腈基苯和二烯氟代金刚烷结构的化合物和用途
CN104447485A (zh) * 2015-01-13 2015-03-25 佛山市赛维斯医药科技有限公司 一种含腈基苯和二烯金刚烷结构的化合物、其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624941A (en) * 1992-06-23 1997-04-29 Sanofi Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present
WO2004058249A1 (fr) * 2002-12-24 2004-07-15 Astrazeneca Ab Derives de 1,5-diaryl-pyrrole-3-carboxamide et leur utilisation en tant que modulateurs des recepteurs des cannabinoides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624941A (en) * 1992-06-23 1997-04-29 Sanofi Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present
WO2004058249A1 (fr) * 2002-12-24 2004-07-15 Astrazeneca Ab Derives de 1,5-diaryl-pyrrole-3-carboxamide et leur utilisation en tant que modulateurs des recepteurs des cannabinoides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CERRETO F ET AL: "Studies on anti-Candida agents with a pyrrole moiety. Synthesis and microbiological activity of some 3-(aminomethyl)-1,5-diaryl-2- methylpyrrole derivatives", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 27, 1992, pages 701 - 708, XP002230620, ISSN: 0223-5234 *

Also Published As

Publication number Publication date
BRPI0608866A2 (pt) 2010-02-02
SV2007002420A (es) 2007-01-17
PA8663601A1 (es) 2006-11-09
FR2882054A1 (fr) 2006-08-18
US20080015245A1 (en) 2008-01-17
TW200714585A (en) 2007-04-16
IL185034A0 (en) 2008-06-05
KR20070103454A (ko) 2007-10-23
EP1853557A2 (fr) 2007-11-14
AU2006215521A1 (en) 2006-08-24
UY29373A1 (es) 2006-10-02
FR2882054B1 (fr) 2007-04-13
RU2007134383A (ru) 2009-03-27
CN101119967A (zh) 2008-02-06
DOP2006000043A (es) 2006-08-31
CA2597033A1 (fr) 2006-08-24
US7524971B2 (en) 2009-04-28
JP2008530187A (ja) 2008-08-07
AR052673A1 (es) 2007-03-28
WO2006087476A2 (fr) 2006-08-24

Similar Documents

Publication Publication Date Title
WO2006087476A3 (fr) Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
NO20044807L (no) Heratitt C virus inhibitorer
NO20062185L (no) Hepatitt C virus-inhibitorer
NO20062267L (no) Hepatitt C virus inhibitorer
NO20091707L (no) Inhibitorer av hepatitt C virus
NO20091704L (no) Inhibitorer av hepatitt C virus
WO2008126889A1 (fr) Composé d'hydrazide et agent contrôlant l'arthropode nocif le contenant
NO20062339L (no) Hepatitt C virus-inhibitoerer
DE602005014804D1 (de) Substituierte 5-carboxyamidpyrazoles und ä1,2,4ütriazole als viruzide
NO20091706L (no) Inhibitorer av hepatitt C virus
CA2620129C (fr) Diaminopyrimidines comme modulateurs p2x3 et p2x2/3
TNSN07252A1 (en) Indole derivatives for treating viral infections
WO2008068424A3 (fr) Derives de 2, 5-dihydro-3h-pyrazolo [4, 3-c] pyridazin-3-one substitues, leur preparation et leur utilisation comme ligands des recepteurs cb1 des cannabinoides
MY144718A (en) Viral polymerase inhibitors.
HRP20130653T1 (en) Pyrrole compounds
NO20091591L (no) Hepatitt C virusinhibitorer
EP1854789A4 (fr) Derive de quinazoline possedant une activite inhibitrice vis-a-vis de la tyrosine kinase
NO20060142L (no) Syklisk tertiaer aminforbindelse
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
CO5640134A2 (es) Derivados de pirrol-2,5-ditiona como moduladores de receptor hepatico x
RS20060315A (en) Derivatives of n-/phenyl(pyrrolidine-2-yl) methyl/benzamide, and n- /(azepan-2-yl)phenylmethyl/benzamide, preparation method thereof and application of same in therapeutics
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
WO2008136444A1 (fr) Dérivé hétérocyclique fusionné
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006709331

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11832851

Country of ref document: US

Ref document number: 185034

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2597033

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/009648

Country of ref document: MX

Ref document number: 2006215521

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680004997.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007555665

Country of ref document: JP

Ref document number: 1020077018738

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3043/KOLNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006215521

Country of ref document: AU

Date of ref document: 20060216

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006215521

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007134383

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006709331

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11832851

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0608866

Country of ref document: BR

Kind code of ref document: A2